# A Study of AK0529 in Infants Hospitalized With RSV

> **NCT02460016** · PHASE1 · TERMINATED · sponsor: **Shanghai Ark Biopharmaceutical Co., Ltd.** · enrollment: 1 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** AK0529

## Key facts

- **NCT ID:** NCT02460016
- **Lead sponsor:** Shanghai Ark Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-08-28
- **Primary completion:** 2015-11-03
- **Final completion:** 2015-11-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** We switched this study design to another study per IEC's recommendations.
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02460016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02460016, "A Study of AK0529 in Infants Hospitalized With RSV". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02460016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*